BioPharmSignal logoBioPharmSignal

Biotech News

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Outlook (OTLK)OutlookFDA / regulatory

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation Company Launches Commercial Franchise Positioned to Establish a New Standard

Related news

OTLKOutlook2026-06-16 12:02 EST

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

OTLKOutlook2026-06-01 12:46 EST

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

HROWHarrow, Inc.2026-08-06 11:00 EST

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

OCSOculis2026-08-03 08:00 EST

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

LENZLenz Therapeutics Inc2026-06-07 23:30 EST

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

OCULOcular Therapeutix2026-09-15 11:00 EST

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

OKYOOKYO Pharma2026-07-08 11:00 EST

OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain

OCSOculis2026-05-07 08:58 EST

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

TARSTarsus Pharmaceuticals2026-08-06 11:01 EST

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

TARSTarsus Pharmaceuticals2026-07-08 20:05 EST

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

View all latest news

Outlook

Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...

Recent company news

OTLKOutlook2026-09-11 11:00 EST

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

OTLKOutlook2026-09-10 13:10 EST

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

OTLKOutlook2026-08-27 20:05 EST

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

OTLKOutlook2026-08-27 13:01 EST

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

OTLKOutlook2026-08-14 11:15 EST

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Stock data

Close
0.65 USD
Market cap
120.89M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States